Cargando…

Inhibition of Casein Kinase II by CX-4945, But Not Yes-associated protein (YAP) by Verteporfin, Enhances the Antitumor Efficacy of Temozolomide in Glioblastoma

Overcoming temozolomide (TMZ) resistance in glioma cancer cells remains a major challenge to the effective treatment of the disease. Increasing TMZ efficacy for patients with glioblastoma (GBM) is urgently needed because TMZ treatment is the standard chemotherapy protocol for adult patients with gli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xiangyu, Chen, Jieyu, Li, Wei, Hang, Chunhua, Dai, Yuyuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2019
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909086/ https://www.ncbi.nlm.nih.gov/pubmed/31810002 http://dx.doi.org/10.1016/j.tranon.2019.09.006

Ejemplares similares

Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma()()()
por: Zakharia, Kais, et al.
Publicado: (2018)

The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies
por: Chon, Hae J., et al.
Publicado: (2015)

Structural Basis for the Selective Inhibition of Cdc2-Like Kinases by CX-4945
por: Lee, Joo Youn, et al.
Publicado: (2019)

Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo
por: Richter, Anna, et al.
Publicado: (2020)

Anti-adipogenic and Pro-lipolytic Effects on 3T3-L1 Preadipocytes by CX-4945, an Inhibitor of Casein Kinase 2
por: Yadav, Anil Kumar, et al.
Publicado: (2022)

Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice
por: Ferrer-Font, Laura, et al.
Publicado: (2017)

Effects of the CK2 Inhibitors CX-4945 and CX-5011 on Drug-Resistant Cells
por: Zanin, Sofia, et al.
Publicado: (2012)

Identification of a Novel Function of CX-4945 as a Splicing Regulator
por: Kim, Hyeongki, et al.
Publicado: (2014)

Structural Determinants of CX-4945 Derivatives as Protein Kinase CK2 Inhibitors: A Computational Study
por: Liu, Hongbo, et al.
Publicado: (2011)

Different Persistence of the Cellular Effects Promoted by Protein Kinase CK2 Inhibitors CX-4945 and TDB
por: Girardi, Cristina, et al.
Publicado: (2015)

CX-4945: the protein kinase CK2 inhibitor and anti-cancer drug shows anti-fungal activity
por: Masłyk, Maciej, et al.
Publicado: (2017)

Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia
por: Klink, Morgann, et al.
Publicado: (2021)

Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells
por: Villamañan, Lucía, et al.
Publicado: (2021)

Verteporfin, a suppressor of YAP–TEAD complex, presents promising antitumor properties on ovarian cancer
por: Feng, Juntao, et al.
Publicado: (2016)

Docking analysis of verteporfin with YAP WW domain
por: Kandoussi, Ilham, et al.
Publicado: (2017)

CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism
por: Lertsuwan, Jomnarong, et al.
Publicado: (2018)

Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945
por: Rosales, Mauro, et al.
Publicado: (2021)

Casein Kinase 2 inhibition sensitizes medulloblastoma to temozolomide
por: Nitta, Ryan T., et al.
Publicado: (2019)

Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy – potential clinical relevance
por: D’Amore, Claudio, et al.
Publicado: (2020)

Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin
por: Brouwer, Niels J., et al.
Publicado: (2021)

Correction: Casein kinase 2 inhibition sensitizes medulloblastoma to temozolomide
por: Nitta, Ryan T., et al.
Publicado: (2019)

Validation of an LC–MS/MS Method for the Quantification of the CK2 Inhibitor Silmitasertib (CX-4945) in Human Plasma
por: Schwarz, Rico, et al.
Publicado: (2022)

PB1810: SELINEXOR COMBINED WITH CX-4945 PROMOTES CELL DEATH BY TARGETING PIK3CD/AKT1/FOXO3 SIGNALING IN ACUTE MYELOID LEUKEMIA
por: Long, Huideng, et al.
Publicado: (2023)

Silmitasertib (CX-4945), a Clinically Used CK2-Kinase Inhibitor with Additional Effects on GSK3β and DYRK1A Kinases: A Structural Perspective
por: Grygier, Przemyslaw, et al.
Publicado: (2023)

CX-4945 and siRNA-Mediated Knockdown of CK2 Improves Cisplatin Response in HPV(+) and HPV(−) HNSCC Cell Lines
por: Trembley, Janeen H., et al.
Publicado: (2021)

Verteporfin exhibits YAP-independent anti-proliferative and cytotoxic effects in endometrial cancer cells
por: Dasari, Venkata Ramesh, et al.
Publicado: (2017)

Inhibition of Yes-Associated Protein by Verteporfin Ameliorates Unilateral Ureteral Obstruction-Induced Renal Tubulointerstitial Inflammation and Fibrosis
por: Jin, Jixiu, et al.
Publicado: (2020)

Artesunate combined with verteporfin inhibits uveal melanoma by regulation of the MALAT1/yes-associated protein signaling pathway
por: Jiu, Xudong, et al.
Publicado: (2021)

MEK Inhibitor PD-0325901 Overcomes Resistance to CK2 Inhibitor CX-4945 and Exhibits Anti-Tumor Activity in Head and Neck Cancer
por: Bian, Yansong, et al.
Publicado: (2015)

YAP Inhibition by Verteporfin Causes Downregulation of Desmosomal Genes and Proteins Leading to the Disintegration of Intercellular Junctions
por: Huang, Yunying, et al.
Publicado: (2022)

The impact of interaction between verteporfin and yes-associated protein 1/transcriptional coactivator with PDZ-binding motif-TEA domain pathway on the progression of isocitrate dehydrogenase wild-type glioblastoma
por: Osama, Mahmoud, et al.
Publicado: (2023)

CK2 Inhibitor CX-4945 Blocks TGF-β1-Induced Epithelial-to-Mesenchymal Transition in A549 Human Lung Adenocarcinoma Cells
por: Kim, Jiyeon, et al.
Publicado: (2013)

OR02-2 CX-4945 as a Potential Drug for Adrenocortical Carcinoma That Induces Multiple Exon-Skipping and Circular RNA of NR5A1
por: Tanaka, Tomoko, et al.
Publicado: (2019)

Casein Kinase 1 Epsilon Regulates Glioblastoma Cell Survival
por: Varghese, Robin T., et al.
Publicado: (2018)

Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway
por: Dong, Liang, et al.
Publicado: (2018)

Verteporfin-induced proteotoxicity impairs cell homeostasis and survival in neuroblastoma subtypes independent of YAP/TAZ expression
por: Condurat, Alexandra-Larisa, et al.
Publicado: (2023)

JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis
por: Tomlinson, V, et al.
Publicado: (2010)

Dual roles of yes-associated protein (YAP) in colorectal cancer
por: Ou, Chunlin, et al.
Publicado: (2017)

Correction: Lertsuwan et al. CX-4945 Induces Methuosis in Cholangiocarcinoma Cell Lines by a CK2-Independent Mechanism. Cancers 2018, 10, 283
por: Lertsuwan, Jomnarong, et al.
Publicado: (2022)

Anti-Growth, Anti-Angiogenic, and Pro-Apoptotic Effects by CX-4945, an Inhibitor of Casein Kinase 2, on HuCCT-1 Human Cholangiocarcinoma Cells via Control of Caspase-9/3, DR-4, STAT-3/STAT-5, Mcl-1, eIF-2α, and HIF-1α
por: Wang, Saini, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_orbsqcg58ho9v9o45ucd58qml3